• Home
  • Asciminib 40mg
  • Asciminib 40mg

Asciminib 40mg

52124

Asciminib is used for adults with Philadelphia chromosome-positive chronic myeloid leukaemia in the chronic phase, including people newly diagnosed in some countries.

It is also used when chronic-phase chronic myeloid leukaemia has already been treated with other tyrosine kinase inhibitors, or when the cancer has a T315I mutation.

Usual adult dose range: 40mg twice daily or 80 mg once daily for many chronic myeloid leukaemia regimens, and 200mg twice daily for disease with the T315I mutation.

Indications vary by country and change over time; this website contains information for general patient information and should be checked against local prescribing information before clinical use.

Verification Approach: Each indication and usual dose-range sentence was drafted from at least two recognised medicines information sources, usually FDA/DailyMed or an FDA label plus EMA/eMC, MedlinePlus, Mayo Clinic, Cancer Research UK, NCI/ Cancer.gov, or another reputable medicines-information source. Doses are general adult/patient-information ranges and must not be used to prescribe or change treatment.
  • FDA/DailyMed prescribing information and FDA Oncology/Hematology approval notifications.
  • EMA and UK eMC Summary of Product
    Characteristics and patient leaflets where available.
  • NCI Cancer Drug Information/Cancer.gov and Cancer Research UK medicine information where available.
  • MedlinePlus, NHS/NICE, and other national medicines information for non-oncology or immune/respiratory medicines.
  • Peer-reviewed FDA approval summaries or manufacturer regulatory notices for very new, withdrawn, or region-specific
    indications.